Loading organizations...
§ Private Profile · 1601 South De Anza Blvd Suite 215 Cupertino, California 95014
Medical devices, orthopedic implants for osteoarthritis treatment. Develops CMC Spacers to separate bones in degenerated joints.
Articulinx Inc. is a Cupertino, California-based medical device company that develops minimally invasive treatments for orthopedic patients suffering from osteoarthritis. The organization's primary commercial product is the Articulinx CMC Spacer, a specialized orthopedic implant designed to act as a physical barrier separating bones in degenerated joints. This therapeutic device is surgically inserted through a small incision utilizing local anesthesia, specifically targeting joint degeneration without requiring extensive reconstructive surgery. Operating under a traditional venture capital business model, the enterprise successfully secured $10 million in a second funding round, with its initial and most recent capital raise recorded on April 13, 2010. The company's scientific advisory board includes notable medical industry figures such as scientific advisor Kurt Huang. Currently, the exact founding year and the identities of the original corporate founders remain publicly undisclosed across standard industry databases.
Articulinx Inc. has raised $12.0M across 2 funding rounds.
Articulinx Inc. has raised $12.0M in total across 2 funding rounds.
# Articulinx Inc. - Medical Device Company Overview
Articulinx is not a technology company in the traditional sense, but rather a medical device manufacturer developing minimally invasive implants for osteoarthritis treatment. The company focuses on orthopedic solutions that preserve joint function rather than requiring bone resection.
Articulinx develops implantable spacer devices designed to treat osteoarthritis, particularly in the carpometacarpal (CMC) joint of the thumb.[1][4] The company's flagship product, the Intercarpometacarpal Cushion (ICMC), addresses a significant clinical problem: bone-on-bone contact that occurs when articular cartilage degenerates, causing pain and reduced mobility.[4]
The company serves patients with osteoarthritis who would otherwise require invasive surgical procedures involving bone or tissue removal. Articulinx's value proposition centers on offering a joint-preserving alternative that maintains future treatment options for patients, rather than permanently altering joint anatomy.[4] This approach represents a meaningful shift in how orthopedic surgeons can manage degenerative joint disease.
Articulinx operates within the orthopedic implant market, addressing the growing burden of osteoarthritis as populations age. The company's focus on joint-preserving solutions aligns with a broader industry trend toward less invasive surgical alternatives that improve patient outcomes and reduce recovery times. By offering a middle ground between conservative management and destructive surgery, Articulinx positions itself in an underserved segment of orthopedic care.
The timing is favorable: osteoarthritis affects millions globally, and healthcare systems increasingly value solutions that reduce surgical morbidity while maintaining long-term flexibility in patient treatment pathways.
Articulinx's success depends on advancing the ICMC through clinical trials and regulatory approval while refining device durability based on real-world performance data. The company's demonstrated ability to iterate on design challenges—such as the radiopaque marker fatigue issue—suggests engineering maturity. Future growth will likely hinge on expanding indications beyond CMC-1 osteoarthritis to other joints affected by degenerative disease, and on building surgeon adoption through clinical evidence and training programs.
The broader orthopedic implant market continues to reward companies offering innovative alternatives to traditional approaches, positioning Articulinx to capture meaningful market share if clinical outcomes continue to validate the joint-preservation strategy.
Articulinx Inc. has raised $12.0M across 2 funding rounds. Most recently, it raised $2.0M Series U in September 2012.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2012 | $2M Series U | — | U.S. Venture Partners | Announced |
| Apr 1, 2010 | $10M Series B | U.S. Venture Partners | DE Novo Ventures | Announced |
Articulinx Inc. has raised $12.0M in total across 2 funding rounds.
Articulinx Inc.'s investors include U.S. Venture Partners, De Novo Ventures.